ASP Isotopes Inc. discloses material events, capital structure, governance matters, operating results and project risks through its SEC filings. The company’s 8-K reports document business updates tied to isotope enrichment, PET Labs radiopharmaceutical operations, Quantum Leap Energy, research collaborations, advisory-board matters, and Renergen-related helium and LNG project disclosures.
Its filings also include Regulation FD exhibits, amended 8-K risk-factor disclosures, and a Form 12b-25 notice for annual-report timing. Recurring disclosure subjects include ASP and Quantum Enrichment technologies, Pretoria enrichment facilities, nuclear medicine and semiconductor isotope applications, nuclear fuel-cycle initiatives, financial position, forward-looking statements, permitting, development costs, and operational risks at the Virginia Gas Project.
AWM Investment Company, Inc. reports beneficial ownership of 619,874 shares of ASP Isotopes Inc. common stock, representing 6.9% of the class. The shares are held by Special Situations Private Equity Fund, L.P. (SSPE), for which AWM acts as investment adviser, and AWM states it holds sole voting and sole dispositive power over these shares.
The filing identifies David M. Greenhouse and Adam C. Stettner as members of MG Advisers, L.L.C., the general partner of SSPE, and as controlling principals of AWM. The report includes a certification that the securities are held in the ordinary course of business and were not acquired for the purpose of changing or influencing control.
ASP Isotopes Inc. (ASPI) filed an 8-K disclosing Item 8.01 – Other Events. The company announced, via the attached 8-Aug-2025 press release, its expected commencement of a dual listing on the Johannesburg Stock Exchange (JSE). Management believes the additional listing will complement the existing Nasdaq quotation under ticker ASPI. No financial statements, guidance, or transactional details were provided in the filing. Exhibit 99.1 contains the full release (except its 6th-7th paragraphs), while Exhibit 104 supplies the Inline XBRL cover page data.
The dual-listing plan may widen ASPI’s investor base, improve liquidity and brand visibility in South Africa, but will also subject the company to JSE regulatory requirements and incremental compliance costs. No timeline, capital raise, or pricing information was included.
ASP Isotopes Inc. (ASPI) disclosed a material definitive agreement on 28 Jul 2025. The company is investing $5 million to acquire 2 million Series Seed-1 Preferred shares of privately held IsoBio, Inc. at $2.50 per share.
- Strategic fit: IsoBio develops antibody-isotope conjugate radiotherapeutics; ASPI gains exposure to oncology applications that can expand its isotope value chain.
- Governance rights: ASPI secures 1 of 3 IsoBio board seats, broad veto rights over major corporate actions, and weighted-average anti-dilution protection.
- Conversion terms: Preferred is convertible 1:1 into IsoBio common at $2.50, automatically upon ≥ $50 m IPO or 2/3 holder consent; shares are non-redeemable.
- Ancillary agreements: Investors’ Rights, ROFR/Co-Sale, and Voting pacts grant ASPI demand registration, first-offer rights, and opportunity to buy stock before key holders sell.
- Related-party aspect: ASPI CEO Paul Mann and director Todd Wider are also designated IsoBio directors, creating potential conflicts but ensuring oversight.
- Next steps: Management will discuss IsoBio on a 30 Jul 2025 investor call; slide deck filed as Exhibit 99.1.
No immediate financial results were provided; cash outflow and future dilution depend on IsoBio’s capital needs and exit timeline.
ASP Isotopes Inc. (Nasdaq: ASPI) filed an 8-K dated 28 Jul 2025 to disclose a joint press release with IsoBio, Inc. announcing IsoBio’s initial Series Seed financing. The funds will be used to advance IsoBio’s proprietary Antibody-Isotope Conjugate platform (AICs TM) aimed at oncology indications.
The companies will host an investor webcast on 30 Jul 2025 at 10:00 a.m. ET to discuss the collaboration. No dollar amount, valuation or ownership details were provided in the filing. The press release is furnished as Exhibit 99.1 (excluding its fifth and sixth paragraphs). No other items, financial statements or pro-forma data accompanied the report.
For ASPI, the disclosure signals strategic expansion into radiopharma-enabled biologics but carries limited immediate financial visibility. The filing is informational and does not amend prior guidance or trigger accounting changes.
On 23 Jul 2025 ASP Isotopes Inc. (ASPI) executed an Underwriting Agreement with Cantor Fitzgerald covering a registered direct offering of 7,500,000 common shares at $8.00 each. The underwriters will acquire the shares at $7.52, reflecting customary underwriting fees.
ASPI projects net proceeds of ≈ $56.2 million after commissions and expenses. Closing is slated for 25 Jul 2025, subject to standard conditions, under the company’s effective Form S-3 shelf (File No. 333-286860) and a related Rule 462(b) registration statement.
Simultaneously, the company terminated its unused $25 million at-the-market Equity Distribution Agreement with Canaccord Genuity, opting instead for the fully underwritten raise. Exhibits include the underwriting agreement (1.1), Blank Rome LLP legal opinion (5.1), and a pricing press release (99.1).
ASP Isotopes (Nasdaq: ASPI) is raising $60 million through a firmly underwritten public offering of 7.5 million new shares at $8.00, a 20% discount to the $10.00 last close. After $3.6 million in underwriting fees and $0.2 million expenses, net proceeds will be ≈$56.2 million. Outstanding shares will rise 9% to 91.6 million, creating immediate dilution of $6.80 per share; adjusted tangible book value moves from $0.54 to $1.20.
Management plans to deploy cash for general corporate purposes and cap-ex as it transitions from commissioning to initial commercial production of C-14, Si-28 and Yb-176 in 2025. Pro-forma cash (3/31/25 balance $56 million + summer raises + this offering) extends the runway beyond 12 months.
Strategic catalysts include: 1) a $22 million TerraPower loan and two HALEU supply agreements valued up to $4.1 billion over 2027-37 (subject to licensing and plant completion); 2) the proposed all-stock acquisition of Renergen (max 14.27 million ASPI shares) to add helium/LNG assets; 3) a planned H2-25 spin-out of Quantum Leap Energy, its HALEU subsidiary. Each transaction faces regulatory, funding and execution risk.
The company remains pre-revenue, reporting <$8.4 million> Q1-25 net loss and <$32.3 million> FY-24 loss, and warns it may need additional capital. Shares have traded between $0.32 and $10.49 since IPO, highlighting volatility.
ASP Isotopes (ASPI) is raising $60 M gross ($56.4 M net) via a 7.5 M share follow-on priced at $8, a 20% discount to the $10.00 last sale. The new total share count will be about 91.6 M. Proceeds are earmarked for general corporate purposes and extend liquidity beyond 12 months; cash at 3/31/25 was $56 M and the company has since raised an additional $51.7 M.
The company is commercialising isotope-enrichment technologies (ASP & QE) and reports commissioning of three South African plants (C-14, Si-28, Yb-176) with first product expected in 2025. Major strategic actions include: 1) $22 M TerraPower loan plus two HALEU supply agreements valued up to $4.1 B through 2037; 2) planned spin-out of Quantum Leap Energy (HALEU & Li-6) in H2-25; and 3) an all-share acquisition of Renergen (up to 14.27 M ASPI shares) that would add helium/LNG assets, pending multiple regulatory approvals.
ASPI remains pre-revenue, logging net losses of $8.4 M in Q1-25 and $32.3 M in FY-24. The offer dilutes existing holders by an estimated $6.80 per share of tangible book value. Underwriters Cantor and Canaccord will deliver shares on or about 25 Jul 25; lock-ups run 90 days (company) and 75 days (insiders).
On July 11, 2025, ASP Isotopes Inc. (NASDAQ: ASPI) filed a Form 8-K (Item 8.01) to disclose that shareholders of Renergen Limited have approved the scheme of arrangement for ASP Isotopes’ proposed acquisition. The approval eliminates a major condition precedent and materially advances the transaction toward closing. A press release describing the vote is attached as Exhibit 99.1 (the fifth and sixth paragraphs are expressly excluded from incorporation by reference).
The filing contains no purchase price, financing structure, or anticipated closing timetable, and it includes no additional financial statements under Item 9.01 beyond the press-release exhibit. Accordingly, the report functions primarily as a regulatory notice highlighting a positive milestone in ASP Isotopes’ M&A strategy rather than providing quantitative information.